ARC-520: Phase IIa started

Arrowhead began a double-blind, placebo-controlled, dose-escalation, Hong Kong Phase IIa trial to evaluate single doses of 1 and 2 mg/kg IV ARC-520 in combination with entecavir in about 16 hepatitis ...